高敏C反应蛋白增强脂蛋白(a)与心血管风险的关联以及阿利西尤单抗的临床获益。 - Suppr

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab.

作者信息

Schwartz Gregory G, Szarek Michael, Zeiher Andreas, White Harvey D, Jukema J Wouter, Harrington Robert A, Goodman Shaun G, Diaz Rafael, Bittner Vera, Bhatt Deepak L, Steg Ph Gabriel

出版信息

J Am Coll Cardiol. 2022 Dec 13;80(24):2356-2359. doi: 10.1016/j.jacc.2022.09.035. Epub 2022 Oct 31.

DOI:10.1016/j.jacc.2022.09.035

PMID:36328873

Abstract

摘要

相似文献

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab.高敏C反应蛋白增强脂蛋白(a)与心血管风险的关联以及阿利西尤单抗的临床获益。

J Am Coll Cardiol. 2022 Dec 13;80(24):2356-2359. doi: 10.1016/j.jacc.2022.09.035. Epub 2022 Oct 31.

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.依洛尤单抗对急性冠状动脉综合征后脂蛋白(a)和心血管风险的影响。

J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. doi: 10.1016/j.jacc.2019.10.057.

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.PCSK9 抑制剂对脂蛋白(a)的降低作用与主要不良心血管事件：依洛尤单抗 3 期临床试验的汇总分析。

Atherosclerosis. 2019 Sep;288:194-202. doi: 10.1016/j.atherosclerosis.2019.06.896. Epub 2019 Jun 8.

Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂降低脂蛋白(a)水平并降低心血管疾病风险

Atherosclerosis. 2022 Nov;361:30-31. doi: 10.1016/j.atherosclerosis.2022.10.010. Epub 2022 Oct 21.

From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.从脂蛋白吸附术到前蛋白转化酶枯草溶菌素 9 抑制剂：对心血管疾病患者的低密度脂蛋白胆固醇和 C 反应蛋白水平的影响。

Eur J Prev Cardiol. 2018 Nov;25(17):1843-1851. doi: 10.1177/2047487318792626. Epub 2018 Jul 30.

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.脂蛋白(a)与 LDL 胆固醇控制良好患者接受 PCSK9 抑制剂治疗的获益。

J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102.

European Atherosclerosis Society screening recommendations for lipoprotein(a) and high-sensitivity C-reactive protein: double standard or failure of evidence-based medicine?欧洲动脉粥样硬化协会关于脂蛋白(a)和高敏C反应蛋白的筛查建议：双重标准还是循证医学的失败？

Clin Chem. 2010 Oct;56(10):1544-6. doi: 10.1373/clinchem.2010.152694. Epub 2010 Aug 11.

Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.脂蛋白（a）、高敏C反应蛋白与接受经皮冠状动脉介入治疗患者的心血管风险

Atherosclerosis. 2022 Dec;363:109-116. doi: 10.1016/j.atherosclerosis.2022.10.013. Epub 2022 Oct 25.

Use of lipoprotein(a) for refining cardiovascular risk prediction in a low-risk population: The CoLaus/PsyCoLaus study.脂蛋白(a)在低风险人群中用于优化心血管风险预测：CoLaus/PsyCoLaus研究

Eur J Prev Cardiol. 2021 Jul 23;28(8):e18-e20. doi: 10.1177/2047487320938271. Epub 2020 Jul 5.

PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).阿利西尤单抗抑制 PCSK9 可增加他汀类药物治疗的脂蛋白(a)升高患者脂蛋白(a)颗粒的代谢。

Metabolism. 2020 Jun;107:154221. doi: 10.1016/j.metabol.2020.154221. Epub 2020 Mar 30.

引用本文的文献

Lipoprotein(a), High-Sensitivity C-Reactive Protein, and All-Cause Mortality in a Primary Prevention Cohort.初级预防队列中的脂蛋白（a）、高敏C反应蛋白与全因死亡率

JACC Adv. 2025 Jun;4(6 Pt 2):101783. doi: 10.1016/j.jacadv.2025.101783.

Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.系统性炎症与接受动脉粥样硬化性心血管疾病治疗患者的健康结局。

Eur Heart J. 2024 Nov 21;45(44):4719-4730. doi: 10.1093/eurheartj/ehae557.

Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study.载脂蛋白(a)和高敏 C 反应蛋白对急性心肌梗死患者全因死亡和心血管死亡风险的协同作用：一项大型前瞻性队列研究。

Front Endocrinol (Lausanne). 2024 May 15;15:1392859. doi: 10.3389/fendo.2024.1392859. eCollection 2024.

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?脂蛋白（a）、白细胞介素-6抑制剂与动脉粥样硬化性心血管疾病：存在关联吗？

Atheroscler Plus. 2023 Sep 9;54:1-6. doi: 10.1016/j.athplu.2023.09.001. eCollection 2023 Dec.

Association of Inflammation and Lipoprotein(a) With Aortic Valve Calcification.炎症和脂蛋白(a)与主动脉瓣钙化的关联。

JACC Cardiovasc Imaging. 2023 Sep;16(9):1230-1232. doi: 10.1016/j.jcmg.2023.02.013. Epub 2023 Apr 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab.

作者信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献